
Interpreting GEP Results in Melanoma: Limitations and Patient-Centered Care
GEP testing is most useful when it is applied to the right patient and read in context. Dr. Singh outlines where testing adds little, how to weigh results, and what a low-risk score offers.
Episodes in this series

This episode of Expert Perspectives "Interpreting GEP Results in Melanoma: Limitations and Patient-Centered Care" features Dr. Singh examining the limits of GEP testing and how to interpret results responsibly.
Dr. Singh says gene expression profiling, like any tool, is most beneficial when used in the right patient. He does not find it useful in stage III melanoma that has already spread to the lymph nodes. In that setting, estimating local recurrence is not typically the clinical question he is trying to answer.
He also urges caution in interpretation, because each result is specific to the individual patient. A report may show, for example, a 9.7% risk of nodal involvement. Decisions about added surgery or imaging must still account for the patient's goals of care, overall health, and functional status. A 9.7% risk may mean something very different in a fit patient than a 12% risk in someone with poor functional status. He emphasizes treating the patient in front of you, not the lab value and not the cancer.
Dr. Singh then addresses a common question from patients and clinicians: why management sometimes does not change after testing. He stresses that management will not change 100% of the time, and that is expected. A Class 1, low-risk result is still very valuable because it eases patient anxiety and burden. He says he often uses GEP testing specifically to reduce that anxiety. Conversely, about a quarter of patients with high-risk results, such as Class 2B, develop metastasis. That is not every patient, but it identifies a subset who need closer imaging follow-up.
He acknowledges that some patients deemed low risk still have poor outcomes, despite sensitivity and specificity in the upper 90s. In those cases, he notes, staging failed the patient as well. He closes by encouraging clinicians to consider GEP testing, citing the volume of supporting data and its association with improved survival.
The final episode, "Combining GEP Testing and ctDNA for High-Risk Melanoma Surveillance," looks ahead as Dr. Singh explains how he pairs GEP testing with circulating tumor DNA monitoring in high-risk patients.
Related to this article









